Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial

Childhood Acute Lymphoblastic Leukaemia

Lymphoblastic Leukaemia ◽

Pulse Therapy ◽

Open Label ◽

Phase 3 ◽

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00363-0 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1677-1690 ◽

Cited By ~ 101

Author(s):

Andrew E Place ◽

Kristen E Stevenson ◽

Lynda M Vrooman ◽

Marian H Harris ◽

Sarah K Hunt ◽

...

Keyword(s):

Escherichia Coli ◽

Lymphoblastic Leukaemia ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Faculty Opinions recommendation of Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725924636.793524748 ◽

2016 ◽

Author(s):

Jan Starý

Keyword(s):

Escherichia Coli ◽

Lymphoblastic Leukaemia ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Faculty Opinions recommendation of Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725924636.793530156 ◽

2017 ◽

Author(s):

Kjeld Schmiegelow

Keyword(s):

Escherichia Coli ◽

Lymphoblastic Leukaemia ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30154-7 ◽

2017 ◽

Vol 18 (4) ◽

pp. 515-524 ◽

Cited By ~ 35

Author(s):

Stine Nygaard Nielsen ◽

Kathrine Grell ◽

Jacob Nersting ◽

Jonas Abrahamsson ◽

Bendik Lund ◽

...

Keyword(s):

Maintenance Therapy ◽

Lymphoblastic Leukaemia ◽

Relapse Free Survival ◽

Phase 3 ◽

Free Survival ◽

Thioguanine Nucleotide

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

The Lancet Haematology ◽

10.1016/s2352-3026(17)30103-5 ◽

2017 ◽

Vol 4 (8) ◽

pp. e387-e398 ◽

Cited By ~ 88

Author(s):

Hagop M Kantarjian ◽

Daniel J DeAngelo ◽

Anjali S Advani ◽

Matthias Stelljes ◽

Partow Kebriaei ◽

...

Keyword(s):

Adverse Event ◽

Lymphoblastic Leukaemia ◽

Adult Patients ◽

Adverse Event Profile ◽

Open Label ◽

Inotuzumab Ozogamicin ◽

Phase 3 ◽

Hepatic Adverse Event

Day Care in Infancy and Risk of Childhood Acute Lymphoblastic Leukaemia: Findings From UK Case-Control Study

Yearbook of Pediatrics ◽

10.1016/s0084-3954(08)70241-0 ◽

2007 ◽

Vol 2007 ◽

pp. 437-439

Author(s):

J.A. Stockman

Keyword(s):

Lymphoblastic Leukaemia ◽

Day Care ◽

Case Control Study ◽

Case Control ◽

Control Study

Screening for the P2RY8-CRLF2 fusion gene in childhood acute lymphoblastic leukaemia

Klinische Pädiatrie ◽

10.1055/s-0031-1277073 ◽

2011 ◽

Vol 223 (03) ◽

Author(s):

M Morak ◽

R Joas ◽

S Fischer ◽

A Attarbaschi ◽

G Mann ◽

...

Keyword(s):

Childhood Acute Lymphoblastic Leukaemia

Lymphoblastic Leukaemia ◽

Fusion Gene ◽

Faculty Opinions recommendation of Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1034.458524 ◽

2005 ◽

Author(s):

Vaskar Saha

Keyword(s):

High Risk ◽

Complete Remission ◽

Prospective Study ◽

Lymphoblastic Leukaemia ◽

Allogeneic Transplantation ◽

Very High ◽

First Complete Remission

Faculty Opinions recommendation of Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725402243.793506131 ◽

2015 ◽

Author(s):

Jan Starý ◽

Michaela Kotrová

Keyword(s):

Prospective Study ◽

Minimal Residual Disease ◽

Lymphoblastic Leukaemia ◽

Clinical Utility ◽

Residual Disease ◽

A Prospective Study ◽

Minimal Residual

Faculty Opinions recommendation of Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726056554.793524745 ◽

2016 ◽

Author(s):

Jan Starý

Keyword(s):

Lymphoblastic Leukaemia ◽

Dexamethasone Therapy